Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine
Watanabe, Moe, Kopruszinski, Caroline Machado , Moutal, Aubin , Ikegami, Daigo , Chen, Yanxia , Ross, Sarah, Mackenzie, Kimberly D., Stratton, Jennifer , Navratilova, Edita , Kopruszinski, Caroline , Khanna, Rajesh , Dodick, David W. , Navratilova, Edita , Porreca, Frank

Mayo Clinic

Brain | March 22, 2022 | Volume: 145 | Issue: 8 | Pages: 2894-2909

10.1093/brain/awac104 | PMID 35325034 Get It

AbstractMigraine headache results from activation of meningeal nociceptors, however, the hypothalamus is activated many hours before the emergence of pain. How hypothalamic neural mechanisms may influence trigeminal nociceptor function remains unknown. Stress is a common migraine trigger that engages hypothalamic dynorphin/kappa opioid receptor (KOR) signalling and increases circulating prolactin. Prolactin acts at both long and short prolactin receptor isoforms that are expressed in trigeminal afferents. Following downregulation of the prolactin receptor long isoform, prolactin signalling at the prolactin receptor short isoform sensitizes nociceptors selectively in females. We hypothesized that stress may activate the kappa opioid receptor on tuberoinfundibular dopaminergic neurons to increase circulating prolactin leading to female-selective sensitization of trigeminal nociceptors through dysregulation of prolactin receptor isoforms.A mouse two-hit hyperalgesic priming model of migraine was used. Repeated restraint stress promoted vulnerability (i.e. first-hit priming) to a subsequent subthreshold (i.e. second-hit) stimulus from inhalational umbellulone, a TRPA1 agonist. Periorbital cutaneous allodynia served as a surrogate of migraine-like pain. Female and male KORCre; R26lsl-Sun1-GFP mice showed a high percentage of KORCre labelled neurons co-localized in tyrosine hydroxylase-positive cells in the hypothalamic arcuate nucleus. Restraint stress increased circulating prolactin to a greater degree in females. Stress-primed, but not control, mice of both sexes developed periorbital allodynia following inhalational umbellulone. Gi-DREADD activation (i.e. inhibition through Gi-coupled signalling) in KORCre neurons in the arcuate nucleus also increased circulating prolactin and repeated chemogenetic manipulation of these neurons primed mice of both sexes to umbellulone. Clustered regularly interspaced short palindromic repeats–Cas9 deletion of the arcuate nucleus KOR prevented restraint stress-induced prolactin release in female mice and priming from repeated stress episodes in both sexes. Inhibition of circulating prolactin occurred with systemic cabergoline, a dopamine D2 receptor agonist, blocked priming selectively in females. Repeated restraint stress downregulated the prolactin receptor long isoform in the trigeminal ganglia of female mice. Deletion of prolactin receptor in trigeminal ganglia by nasal clustered regularly interspaced short palindromic repeats–Cas9 targeting both prolactin receptor isoforms prevented stress-induced priming in female mice.Stress-induced activation of hypothalamic KOR increases circulating prolactin resulting in trigeminal downregulation of prolactin receptor long and pain responses to a normally innocuous TRPA1 stimulus. These are the first data that provide a mechanistic link between stress-induced hypothalamic activation and the trigeminal nociceptor effectors that produce trigeminal sensitization and migraine-like pain. This sexually dimorphic mechanism may help to explain female prevalence of migraine. KOR antagonists, currently in phase II clinical trials, may be useful as migraine preventives in both sexes, while dopamine agonists and prolactin/ prolactin receptor antibodies may improve therapy for migraine, and other stress-related neurological disorders, in females.
Reply to A. Smith et al
Fontana, Elisa , Meyers, Jeffrey P., André, Thierry , Ben‐Aharon, Irit , Shi, Qian , André, Thierry , Shi, Qian , Fontana, Elisa

Mayo Clinic

Journal of Clinical Oncology | March 22, 2022 | Volume: 40 | Issue: 16 | Pages: 1844-1846

10.1200/jco.22.00246 | PMID 35316071 Get It

Abstract 193: Cerebral Cavernous Malformation Location and Mode of Presentation Predict the Risk of Hemorrhage During Their Untreated Clinical Course: Individual Patient Data Meta-Analysis
Su, I‐Chang , Brown, Robert D. , Christianson, Teresa J., Agid, Ronit , terBrugge, Karel G. , Willinsky, Robert A., Collaborators, Cerebral Cavernous Malformation Individual PatientData Meta-Analysis, Horne, Margaret A, Flemming, Kelly D. , Stapf, Christian , Maxwell, Susanne Sarah , Murray, Gordon D. , Salman, Rustam Al‐Shahi , Collaborators, Cerebral Cavernous Malformation Individual PatientData Meta-Analysis

Mayo Clinic

Stroke | March 20, 2022 | Volume: 46 | Issue: suppl_1 | Pages: No page available

10.1161/str.46.suppl_1.193 Get It

INTRODUCTION: Cerebral cavernous malformations (CCM) are the second commonest incidental finding on brain MRI and may cause symptomatic intracranial hemorrhage (ICH). However, the risk and predictors of ICH from CCM remain uncertain. HYPOTHESIS: Presentation with ICH or non-hemorrhagic focal neurological deficit (FND) attributable to CCM, brainstem CCM location, female sex, increasing age and multiple CCM predict ICH occurrence during follow-up without CCM treatment. METHODS: Three hospital-based cohorts and two cohorts from a population-based study provided individual patient data on clinical course from CCM diagnosis until either first CCM treatment or last available follow-up. We used survival analysis of each cohort to estimate the 5-year risk of symptomatic ICH or new FND, multivariable Cox regression to identify baseline predictors of outcome, and random-effects models to pool estimates in meta-analysis. RESULTS: Among 988 adults who experienced 62 ICHs during 3,232 person-years of follow-up, clinical presentation with ICH or FND (hazard ratio [HR] 7.4, 95% confidence interval [CI] 2.9-19.2) and brainstem CCM location (HR 5.7, 95% CI 3.2-10.3) were associated with a higher risk of a first ICH within five years of CCM diagnosis, but age, sex and CCM multiplicity were not. The 5-year estimated risk of ICH during untreated follow-up was 2.4% (95% CI 1.0-3.8) for 566 adults without ICH/FND from CCM outside the brainstem, 5.5% (95% CI 0-12.9) for 51 adults without ICH/FND from brainstem CCM, 10.6% (95% CI 5.1-16.1) for 198 adults with ICH/FND from CCM outside the brainstem, and 25.7% (95% CI 18.3-33.1) for 173 adults with ICH/FND from brainstem CCM. In secondary analyses of first ICH or FND, event rates increased but predictors remained unchanged. CONCLUSION: Mode of clinical presentation and CCM location are independently associated with ICH or FND within five years of CCM diagnosis, which can inform decisions about CCM treatment.
Abstract 341: Optimizing Cardiovascular Disease Research in Women
Wenger, Nanette K. , Taylor, Doris A. , Kaplan, Jay R. , Rich‐Edwards, Janet W. , Miller, Virginia M. , Shaw, Leslee J. , Berga, Sarah L. , Webb, Clinton, Ouyang, Pamela , Reckelhoff, Jane F. , Steiner, Meir , Merz, C. Noel Bairey

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.341 Get It

Cardiovascular (CV) disease (CVD) is the major health burden and cause of death for women. Marked disparities exist in CVD diagnosis, prevention, and treatment between women and men – as well as lack of female-specific data. Population, physiologic, translational, and clinical trial studies of sex and gender differences in CVD [[Unable to Display Character: –]] even when only women are studied[[Unable to Display Character: –]] often do not collect relevant data specific to women that could inform study outcomes. The ISIS CVD Network of the Society for Women’s Health Research compiled an inventory of items specific for women across the lifespan, together with references for methods and strategies to gather and evaluate this information; some items comprise robust measures, others are in development. The objective is to enhance usefulness of CVD research data in understanding sex and gender differences, thereby optimizing healthcare delivery and outcomes for women. Included are hormonal variables (menstrual cycle phase, hormone levels) oral contraceptive use, pregnancy history/complications, polycystic ovary syndrome (PCOS) components, measures of menopause, and menopausal hormone therapy, variables generally not collected in research studies, but essential to determine their role as sex-specific contributors to CV health and disease. Clear associations exist between reproductive health and CV health and disease. For example 25-33% of women experience complications of pregnancy that may precede and predispose to CVD. Vascular complications during pregnancy, antecedent risk factors and subsequent clinical CVD can be ascertained using medical records, birth registries, and/or maternal recall. Evaluating compilations of patient data with known hormonal or menopausal status using reference standards and patient data for PCOS could inform relationships to subsequent CV outcomes. Variables predominant among women that preferentially disadvantage them should be considered; e.g. psychosocial issues and elderly age. Depressive disorders are twice as common among women as men. They adversely affect CVD outcomes in women, yet the effect of reproductive life cycle and of hormonal fluctuations on depression and etiologic contributions of depression to CVD are inadequately explored. In addition to traditional CVD risk factors, diabetes mellitus, chronic inflammatory disorders, oxidative stress, vasomotor dysfunction, coronary microvascular disorders, and other novel risk variables that preferentially impact women should be explored. Along with increased enrollment of women in CVD research studies and analysis of clinical and genetic studies by sex, improvements and expansion of study design must include these understudied uniquely or predominantly female characteristics. This will enhance the quality and quantity of evidence-based medicine to guide CVD care in women and men thereby setting the stage for personalized approach to medicine.
Abstract 215: Validation of a Simple White-light 3D Body Volume Scanner to Assess Body Composition
Jenkins, Sarah M. , Zundel, Jennifer, Johnson, Lynne L. , Jean, Nathalie, Medina‐Inojosa, José R. , Somers, Virend K. , Johnson, Lynne, López-Jiménez, Francisco

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 8 | Issue: suppl_2 | Pages: No page available

10.1161/circoutcomes.8.suppl_2.215 Get It

Introduction: Estimating body fat content has shown to better predict adiposity-related cardiovascular risk than the commonly used body mass index (BMI). The white-light 3D Body Volume Index Scanner (BVI) is a non-invasive device normally used in the clothing industry to asses body shapes and sizes. We assessed the hypothesis that volume obtained by BVI is comparable to the volume obtained by air displacement plethysmography (BodPod) (COSMED Concord, CA, USA) and thus capable of assessing body fat mass using the bicompartmental principles of body composition. Methods: We compared BVI to BodPod, a validated bicompartmental method to assess body fat percent that uses pressure/volume relationships in isothermal conditions to estimate body volume. Volume is then used to calculate body density (BD) applying the formula density= Body mass/Volume. Body fat mass percentage is then calculated using the Siri formula (4.95/BD – 4.50) х 100. Subjects were members of the Mayo Clinic Dan Abraham Healthy Living Center undergoing a wellness evaluation. Measurements from both devices were obtained the same day. A prediction model for total BodPod volume was developed using linear regression based on 80% of the observations (N=971), as follows: Predicted BodPod Volume (L) = 9.498 + 0.805*(BVI volume, L) - 0.0411*(Age, years) - 3.295*(Male=0, Female=1) + 0.0554*(BVI volume, L)*(Male=0, Female=1) + 0.0282*(Age, years)*(Male=0, Female=1). Predictions for BodPod volume based on the estimated model were then calculated for the remaining 20% (N=243) and compared to the volume measured by the BodPod. Results: Mean (SEM) age was 41.5(0.41) years, 39.4% were men, weight 81.6(0.67) kg, BMI was 27.8 (0.20) kg/m2. Average difference between volume measured by BodPod- predicted volume by BVI was 0.0 L, median: -0.4 L, IQR: -1.8 L to 1.5 L. Average difference between Body fat % measured - predicted was -1%, median: -2.7%, IQR: -13.2 to 9.9, R2 = 0.9845 (Figure 1-A, B). Conclusion: Body fat mass can be estimated using volume measurements obtained by a white- light 3D body scanner (Figure 1-A).
Abstract P123: Lipid-lowering Therapy Prescription Patterns and Predictors of High Intensity Statin Prescriptions in Patients With Diabetes or Atherosclerotic Cardiovascular Disease
Killian, Jill M. , Monda, Keri L., Hedgeman, Elizabeth , Weston, Susan A., Okerson, Ted, Chamberlain, Alanna M. , Cohen, Sarah S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 135 | Issue: suppl_1 | Pages: No page available

10.1161/circ.135.suppl_1.p123 Get It

Background: Many patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) do not receive guideline-recommended lipid lowering therapy (LLT). We characterized LLT treatment patterns and identified predictors of high intensity statin prescriptions (Rx) in patients with ASCVD and DM. Methods: Olmsted County, MN residents with DM or ASCVD (MI, unstable angina, revascularization, ischemic stroke/TIA) from 2005-2012 were followed for 2 years capturing all LDL-C and LLT Rx. Cox regression examined predictors of high intensity statin Rx, modeling LDL-C as a time-dependent variable. Results: 8408 patients with DM (n=4881) or ASCVD (n=3527) were identified (mean age 63.1, 55.1% male). Over 2 years, mean (SD) number of LDL-C measurements was 2.7 (1.9); 12.1% had none. Among those with ≥1 LDL-C, the first was ≥100 mg/dL in 46.2%. LLT Rx increased within 30 days after the first LDL-C. (Table). However, among those with LDL-C ≥100, 40.1% were not prescribed LLT; these patients were younger (mean age 56.9 vs 60.8), more likely female (52.7% vs 45.6%) and more likely to have DM vs ASCVD (84.5% vs 54.6%) than those prescribed LLT. High intensity statin Rx increased more for those with LDL-C ≥100 than those with LDL-C <100. Men [HR 1.29 (CI 1.13-1.48)] and patients with ASCVD vs DM [6.12 (5.25-7.12)] were more likely to be prescribed high intensity statins. Higher LDL-C was associated with greater high intensity statin Rx, although associations differed between ASCVD and DM (p-interaction=0.004). Compared to DM, ASCVD patients were more likely prescribed high intensity statins at every level of LDL-C [2.73 (1.70-4.37), 6.47 (4.94-8.47), 5.68 (4.45-7.25), and 7.88 (5.89-10.53) for LDL-C <70, 70-99, 100-130, and ≥130]. Conclusions: Although high intensity statin Rx increased in response to increasing LDL-C, a large proportion of patients do not receive guideline-concordant care. Efforts should be made to encourage more aggressive treatment of elevated LDL-C and to understand why treatment is neglected or delayed.
Exosomes for Regulation of Immune Responses and Immunotherapy
Hussain, Md Walid Akram , Jahangir, Sarah , Ghosh, Bikona , Yesmin, Farjana, Anis, Afnan , Satil, Sabikun Nahar, Anwar, Faizan , Rashid, Mohammad H.

Mayo Clinic

Journal of Nanotheranostics | March 16, 2022 | Volume: 3 | Issue: 1 | Pages: 55-85

10.3390/jnt3010005 Get It

Exosomes are membrane-enveloped nanosized (30–150 nm) extracellular vesicles of endosomal origin produced by almost all cell types and encompass a multitude of functioning biomolecules. Exosomes have been considered crucial players of cell-to-cell communication in physiological and pathological conditions. Accumulating evidence suggests that exosomes can modulate the immune system by delivering a plethora of signals that can either stimulate or suppress immune responses, which have potential applications as immunotherapies for cancer and autoimmune diseases. Here, we discuss the current knowledge about the active biomolecular components of exosomes that contribute to exosomal function in modulating different immune cells and also how these immune cell-derived exosomes play critical roles in immune responses. We further discuss the translational potential of engineered exosomes as immunotherapeutic agents with their advantages over conventional nanocarriers for drug delivery and ongoing clinical trials.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Lheureux, Stéphanie , Konstantinopoulos, Panagiotis A. , Wang, Ben X. , Gadalla, Ramy , Block, Matthew S. , Gaillard, Stéphanie , McHale, Michael , Werner, Theresa L. , Duska, Linda , Kehoe, Siobhan M., Colombo, Ilaria , Wang, Lisa , Wildman, Rachel P., Soleimani, Shirin , Lien, Scott , Wright, John, Pugh, Trevor J. , Pugh, Trevor J , Konstantinopoulos, Panagiotis A , Gaillard, Stéphanie , Matei, Daniela , Jewell, Andrea , McCourt, Carolyn Kay , Temkin, Sarah M. , Girda, Eugenia , Backes, Floor , Li, Xuan , Wildman, Rachel, Wright, John, Ohashi, Pamela S. , Brooks, David G. , Fleming, Gini F.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 14, 2022 | Volume: 10 | Issue: 3 | Pages: e004233

10.1136/jitc-2021-004233 | PMID 35288469 Get It

Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and an antiangiogenic agent (cabozantinib) in immunotherapy-naïve endometrial cancer and in patients whose disease progressed on previous immunotherapy with baseline biopsy for immune profiling. Patients and methods In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11, 2017), women with recurrent endometrial cancer were randomized 2:1 to nivolumab with cabozantinib (Arm A) or nivolumab alone (Arm B). The primary endpoint was Response Evaluation Criteria in Solid Tumors-defined progression-free survival (PFS). Patients with carcinosarcoma or prior immune checkpoint inhibitor received combination treatment (Arm C). Baseline biopsy and serial peripheral blood mononuclear cell (PBMC) samples were analyzed and associations between patient outcome and immune data from cytometry by time of flight (CyTOF) and PBMCs were explored. Results Median PFS was 5.3 (90% CI 3.5 to 9.2) months in Arm A (n=36) and 1.9 (90% CI 1.6 to 3.4) months in Arm B (n=18) (HR=0.59, 90% CI 0.35 to 0.98; log-rank p=0.09, meeting the prespecified statistical significance criteria). The most common treatment-related adverse events in Arm A were diarrhea (50%) and elevated liver enzymes (aspartate aminotransferase 47%, alanine aminotransferase 42%). In-depth baseline CyTOF analysis across treatment arms (n=40) identified 35 immune-cell subsets. Among immunotherapy-pretreated patients in Arm C, non-progressors had significantly higher proportions of activated tissue-resident (CD103+CD69+) ɣδ T cells than progressors (adjusted p=0.009). Conclusions Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune profile and potentially benefiting from combination with antiangiogenics requires further investigation.
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Teachey, David T. , Devidas, Meenakshi , Wood, Brent L. , Chen, Zhiguo , Hayashi, Robert J. , Hermiston, Michelle L. , Annett, Robert D. , Archer, Jan-Michael , Asselin, Barbara L. , August, Keith J. , Fisher, Brian T. , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Wood, Charlotte, Bollard, Catherine M. , Loh, Mignon L. , Raetz, Elizabeth A. , Archer, J Hunter , Dunsmore, Kimberly P , Fisher, Brian T , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Schafer, Eric S , Winter, Stuart S , Bollard, Catherine M , Loh, Mignon L , Hunger, Stephen P , Wood, Brent L , August, Keith , Devidas, Meenakshi , Cho, Steve Y. , Freedman, Jason Lawrence , Messinger, Yoav H. , Schafer, Eric S. , Winter, Stuart S. , Zweidler-McKay, Patrick A , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | March 10, 2022 | Volume: 40 | Issue: 19 | Pages: 2106-2118

10.1200/jco.21.02678 | PMID 35271306 Get It

PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which also attempted to reduce the use of prophylactic cranial radiation (CRT) in newly diagnosed T-ALL. PATIENTS AND METHODS Children and young adults with T-ALL/T-LL were randomly assigned to a modified augmented Berlin-Frankfurt-Münster chemotherapy regimen with/without bortezomib during induction and delayed intensification. Multiple modifications were made to the augmented Berlin-Frankfurt-Münster backbone used in the predecessor trial, AALL0434, including using dexamethasone instead of prednisone and adding two extra doses of pegaspargase in an attempt to eliminate CRT in most patients. RESULTS AALL1231 accrued 824 eligible and evaluable patients from 2014 to 2017. The 4-year event-free survival (EFS) and overall survival (OS) for arm A (no bortezomib) versus arm B (bortezomib) were 80.1% ± 2.3% versus 83.8% ± 2.1% (EFS, P = .131) and 85.7% ± 2.0% versus 88.3% ± 1.8% (OS, P = .085). Patients with T-LL had improved EFS and OS with bortezomib: 4-year EFS (76.5% ± 5.1% v 86.4% ± 4.0%; P = .041); and 4-year OS (78.3% ± 4.9% v 89.5% ± 3.6%; P = .009). No excess toxicity was seen with bortezomib. In AALL0434, 90.8% of patients with T-ALL received CRT. In AALL1231, 9.5% of patients were scheduled to receive CRT. Evaluation of comparable AALL0434 patients who received CRT and AALL1231 patients who did not receive CRT demonstrated no statistical differences in EFS ( P = .412) and OS ( P = .600). CONCLUSION Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse.
The Extracellular ATP Receptor P2RX7 Imprints a Promemory Transcriptional Signature in Effector CD8+ T Cells
Vardam-Kaur, Trupti , Dijk, Sarah van , Peng, Changwei , Wanhainen, Kelsey M. , Jameson, Stephen C. , Silva, Henrique Borges da , van Dijk, Sarah , Borges da Silva, Henrique , Jameson, Stephen C

Mayo Clinic

The Journal of Immunology | March 9, 2022 | Volume: 208 | Issue: 7 | Pages: 1686-1699

10.4049/jimmunol.2100555 | PMID 35264459 Get It

Abstract Development of CD8+ central memory T (Tcm) and resident memory T (Trm) cells, which promote immunity in the circulation and in barrier tissues, respectively, is not completely understood. Tcm and Trm cells may arise from common precursors; however, their fate-inducing signals are elusive. We found that virus-specific effector CD8+ T cells display heterogeneous expression of the extracellular ATP sensor P2RX7. P2RX7-high expression is confined, at peak effector phase, to CD62L+ memory precursors, which preferentially form Tcm cells. Among early effector CD8+ T cells, asymmetrical P2RX7 distribution correlated with distinct transcriptional signatures, with P2RX7-high cells enriched for memory and tissue residency sets. P2RX7-high early effectors preferentially form both Tcm and Trm cells. Defective Tcm and Trm cell formation in P2RX7 deficiency is significantly reverted when the transcriptional repressor Zeb2 is ablated. Mechanistically, P2RX7 negatively regulates Zeb2 expression, at least partially through TGF-β sensing in early effector CD8+ T cells. Our study indicates that unequal P2RX7 upregulation in effector CD8+ T cells is a foundational element of the early Tcm/Trm fate.